Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK3 | O43781 | 1/20 | 0.34 |
| ▸ | ESRRA | P11474 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | ACSL1 | P33121 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.30 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.30 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL648825 | 0.89 | DYRK3 (0.36) | DYRK3CNR1NPSR1MAPTRECQL | |
| SCHEMBL10176525 | 0.85 | ABL1 (0.36) | DYRK3ESRRACNR1NPSR1MAPT | |
| SCHEMBL650221 | 0.85 | ABL1 (0.36) | DYRK3ESRRACNR1NPSR1MAPT | |
| SCHEMBL653447 | 0.83 | MAPT (0.39) | NPSR1MAPTRECQLHPGDMEN1 | |
| SCHEMBL653599 | 0.80 | MAPT (0.40) | NPSR1MAPTRECQLHPGDMEN1 | |
| SCHEMBL650134 | 0.78 | AKR1B1 (0.39) | DYRK3MAPTHPGDMEN1POLB | |
| SCHEMBL653505 | 0.78 | MAPT (0.40) | NPSR1MAPTRECQLHPGDMEN1 | |
| SCHEMBL10176526 | 0.77 | KDR (0.39) | DYRK3PIK3CD | |
| SCHEMBL699754 | 0.75 | KDR (0.38) | DYRK3 | |
| SCHEMBL653362 | 0.75 | MAPT (0.45) | NPSR1MAPTRECQLHPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119812-B2 | Thiazolidinone derivative | SBI BIOTECH CO., LTD. (JP) | 2012-02-21 | — | — | US | disclosed |
| US-20110190299-A1 | THIAZOLIDINONE DERIVATIVE | SBI BIOTECH CO., LTD. (JP) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190299-A1 | THIAZOLIDINONE DERIVATIVE | CDC7, CDK17, CDCA2 | DYRK3 1808/4885ESRRA 1593/4885CNR1 4723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.